Infinity Pharmaceuticals, Inc. (INFIQ)

Market Cap	91.00
Revenue (ttm)	2.57M +15.9%
Net Income	-40.95M
EPS	-0.46
Shares Out	90.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4,994
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	n/a
Beta	7.80
RSI	48.13
Earnings Date	n/a

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company’s product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1995
• Employees: 30
• Stock Exchange: OTCMKTS
• Ticker Symbol: INFIQ

Financial Performance

In 2022, Infinity Pharmaceuticals's revenue was $2.59 million, an increase of 39.56% compared to the previous year's $1.86 million. Losses were -$44.37 million, -1.97% less than in 2021.